Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy
Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy
复制标题
DOI：
10.1691/ph.2018.7948
复制
发表时间：
2018-05-01
期刊：
影响因子：
1.6
通讯作者：
Akashi, K.
中科院分区：
文献类型：
--
作者：
Uchida, M.;Nakamura, T.;Akashi, K.
回顾性评价格拉司琼和帕洛诺司琼对接受苯达莫司汀为主化疗的非霍奇金淋巴瘤患者化疗所致恶心呕吐（CINV）的止吐效果和安全性。共有61例患者有资格参加本研究。在开始基于苯达莫司汀的化疗之前，静脉内给予格拉司琼或帕洛诺司琼，伴或不伴阿瑞匹坦和/或地塞米松。评估了总体（化疗开始后6天内）、急性（最多2天）和延迟（3 - 6天）阶段完全控制（CC）的患者比例。CC定义为完全缓解，仅0-1级恶心，无呕吐，且未使用止吐急救药物。格拉司琼或帕洛诺司琼单独给药9例和19例患者，分别。阿瑞匹坦和/或地塞米松分别联合格拉司琼和帕洛诺司琼28例和5例。所有患者的急性CINV均得到完全控制。格拉司琼单药治疗和帕洛诺司琼联合治疗可以提供良好的控制迟发性CINV，虽然在延迟和整体阶段的CC率之间没有显着差异的单药和联合治疗的止吐药。格拉司琼和帕洛诺司琼治疗组之间药物不良事件的频率没有显著差异。本研究表明，格拉司琼为基础的治疗的止吐疗效和安全性不劣于帕洛诺司琼为基础的治疗。考虑到治疗费用，格拉司琼单药治疗足以预防接受苯达莫司汀化疗的非霍奇金淋巴瘤患者的CINV。
The antiemetic effects and safety of granisetron and palonosetron against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy. A total of 61 patients were eligible for this study. Before starting the bendamustine-based chemotherapy, granisetron or palonosetron were intravenously administered with or without aprepitant and/or dexamethasone. The proportions of patients with complete control (CC) during the overall (during the 6 days after the start of the chemotherapy), acute (up to 2 days), and delayed (3 to 6 days) phases were assessed. CC was defined as complete response with only grade 0-1 nausea, no vomiting, and no use of antiemetic rescue medication. Granisetron or palonosetron alone were administered to 9 and 19 patients, respectively. Aprepitant and/or dexamethasone were combined with granisetron and palonosetron in 28 and 5 patients, respectively. Acute CINV was completely controlled in all patients. Both granisetron monotherapy and palonosetron combination therapy could provide good control of delayed CINV, although the CC rates during the delayed and overall phases were not significantly different among mono- and combination therapy of the antiemetics. There was no significant difference in the frequencies of adverse drug events between the granisetron and palonosetron treatment groups. The present study showed that the antiemetic efficacy and safety of granisetron-based therapy were non-inferior to those of palonosetron-based therapy. Taken together with treatment costs, granisetron monotherapy would be adequate to prevent CINV in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy.